Cerus Corporation (NASDAQ:CERS) and a pharmaceutical unit of Nipro Corporation announced a collaboration agreement. The collaboration will lead to the development of efficient and easy-to-use disposable kit for red cells. The project will benefit from the proprietary technology of Nipro towards the creation a red cell disposable kit that suits the needs of small and large blood centers. Cerus Corporation (NASDAQ:CERS) stock performance was 7.55% in last session and finished the day at $4.13. Traded volume was 1.04million shares in the last session and the average volume of the stock remained 1.15million shares. The beta of the stock remained 2.38. Cerus Corporation (NASDAQ:CERS) insider ownership is 1.10%.

Omeros Corporation (NASDAQ:OMER) announced that the company’s Investigational NDA to evaluate-OMS721 for inhibition of complement and mediated thrombotic-microangiopathies has received clearance from the United States Food & Drug Administration . The company’s OMS721 is a lead human-monoclonal antibody that targets the mannan-binding lectin-that is associated with serine protease-2 (MASP-2). Omeros Corporation (NASDAQ:OMER) rose 7.20 percent to $13.25 Monday on volume of 690,977.00million shares. The intra-day range of the stock was $12.15 to $13.25. Omeros Corporation (NASDAQ:OMER) has a market capitalization of $49.20million.

Durata Therapeutics Inc (NASDAQ:DRTX) is waiting for FDA action set for May 26th. Durata Therapeutics Inc (NASDAQ:DRTX) is up for FDA board pending approval decision for its drug Dalbavancin. Dalbavancin is used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Durata bought Dalbavancin back in September of 2009 from Pfizer after it received a Complete Response Letter from the FDA. Durata Therapeutics Inc (NASDAQ:DRTX)’s stock on May 5, 2014 reported a increase of 5.78% to the closing price of $14.27. Its fifty two weeks range is $6.68 -$16.99. The total market capitalization recorded $380.16million. The overall volume in the last trading session was 590,200.00million shares. In its share capital, DRTX has 26.64million outstanding shares.

Aastrom Biosciences Inc (NASDAQ:ASTM) entered into a definitive agreement to acquire Sanofi’s Cell Therapy & Regenerative Medicine (CTRM) business (currently operating under Genzyme A/S) for a purchase price of $6.5 million or 0.1x LTM revenues. On Monday, shares of Aastrom Biosciences Inc (NASDAQ:ASTM) advanced 7.38% to close the day at $4.51. Company monthly performance is recorded as 7.89%. Aastrom Biosciences Inc (NASDAQ:ASTM) quarterly revenue growth is 29.97%.